Ellular proliferative capability. Co-treatment with BLF501 led to a normal expression
Ellular proliferative capacity. Co-treatment with BLF501 led to a typical expression and distribution of each zonula occludens-1 (ZO-1) and beta-catenin, which had been underexpressed soon after treatment with either chemotherapeutic…